- ImmuCell Corporation (NASDAQ:ICC) reported preliminary Q4 revenue of $7.8 million, up 52% from Q4 2023.
- Co sees FY 2024 sales of $26.5 million, also a 52% increase over 2023.
- The company believes the current backlog reflects strong demand as distributors work to replenish their buffer stocks and end users place orders ahead of the peak calving season during the first quarter.
-
Source: Press release
